STERIS plc

STERIS plc(STE)股票分析

$233.780

+0.818 (+0.35%)收盘时

Loading chart…
High
234.070
Open
233.000
VWAP
232.81
Vol
339.46K
Mkt Cap
21.40B
Low
230.570
Amount
79.03M
EV/EBITDA, TTM
13.57

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

AI analysis of STERIS plc (STE)

buy

Steris plc (STE) is a good buy right now due to its strong earnings performance, with a reported EPS of $2.59 for Q1 2027, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, reaching $1.5 billion. The forward P/E ratio stands at 21.74, suggesting it is reasonably valued compared to its growth prospects. However, the main risk is the decline in operating cash flow, which fell to $367.1 million from $420.0 million year-over-year, indicating potential cash management challenges.

Analyst Ratings (8)

Buy
6 Buy
2 Hold
0 Sell
Current: 233.78
最低
平均
最高

UBS

2026-07-28

目标价

$275

Buy

KeyBanc

2026-05-13

目标价

$269

Overweight

Morgan Stanley

2026-01-08

目标价

Equal Weight

JPMorgan

2025-12-05

目标价

Neutral

KeyBanc

2025-07-22

目标价

$288

Overweight

估值指标

The current forward P/E ratio for STERIS plc (STE) is 21.74, compared to its 5-year average forward P/E of 23.98.

Forward P/E

Fair
5Y Average P/E
23.98
Current P/E
21.74
高估
26.69
低估
21.27

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
16.33
Current EV/EBITDA
13.57
高估
18.67
低估
13.99

Forward P/S

Undervalued
5Y Average P/S
3.95
Current P/S
3.35
高估
4.40
低估
3.50

Alphio AI Price Scenarios for STE

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%STE

$245.24

情景价格

B

Base

Base · 50%STE

$207.79

情景价格

B

Bear

Bear · 25%STE

$150.35

情景价格

Whales holding STE

T

The London Company of Virginia, LLC

+ HoldingSTE

+3.03%

3M Return

C

Colonial Trust Advisors, Inc.

+ HoldingSTE

+2.72%

3M Return

W

Williams Jones Wealth Management, LLC

+ HoldingSTE

+1.38%

3M Return

F

Findlay Park Partners LLP

+ HoldingSTE

+0.39%

3M Return

L

Locust Wood Capital Advisers, LLC

+ HoldingSTE

+0.16%

3M Return

G

GHP Investment Advisors, Inc.

+ HoldingSTE

-2.87%

3M Return

事件时间线

2026-08-05 (ET)

09:31:00

Steris Invests $600M to Build Manufacturing Center in North Carolina

2026-07-30 (ET)

17:00:00

Steris Announces Quarterly Dividend of 69 Cents per Share

2026-05-11 (ET)

16:40:00

Company Reports Q4 Revenue of $1.6B

16:40:00

Sees FY27 Revenue Growth 7%-8% from $5.9B

2026-02-04 (ET)

16:40:00

Company Expects 8-9% Revenue Growth for Fiscal 2026

资讯

STE FAQ — answered by Alphio AI

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Steris plc (STE) is a good buy right now due to its strong earnings performance, with a reported EPS of $2.59 for Q1 2027, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, reaching $1.5 billion. The forward P/E ratio stands at 21.74, suggesting it is reasonably valued compared to its growth prospects. However, the main risk is the decline in operating cash flow, which fell to $367.1 million from $420.0 million year-over-year, indicating potential cash management challenges.

8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始